15 completed, 9 recruiting, 3 not yet recruiting, 2 active not recruiting. 32 Phase 1, 13 Phase 2.
Follow Orbital Diseases: new trials by email Literature Review of Orbital Diseases trials Research Report on Orbital Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD) REGN24493, Placebo - Graves' Disease | Phase 1 | Not yet recruiting | Regeneron Pharmaceuticals | 45 | 2026-11-02 | 2026-10-06 |
| Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 1 | Not yet recruiting | Banu Aji Dibyasakti | 64 | 2026-08-30 | 2026-08-13 |
| Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease ETHY-001, Placebo - Thyroid Eye Disease (TED), Graves' Disease | Phase 1 | Recruiting | Ethyreal Bio, Inc. | 72 | 2026-07-06 | 2026-10-26 |
| A Study of IBI3031 in Participants With Thyroid Eye Disease IBI3031, placebo - Thyroid Eye Disease | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 66 | 2026-06-30 | 2026-07-14 |
| A Clinical Study of Cizutamig in Thyroid Eye Disease Cizutamig will be dosed according to the protocol. - Thyroid Eye Disease, TED | Phase 1 | Recruiting | Candid Therapeutics | 38 | 2026-05-08 | 2026-09-01 |
| A Study of VV-14305 for the Treatment of Thyroid Eye Disease VV-14305, Sham (No Treatment) - Thyroid Eye Disease (TED) | Phase 1 / Phase 2 | Recruiting | Kriya Therapeutics, Inc. | 135 | 2026-05-01 | 2026-08-27 |
| An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NTB003, NTB003 and Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 74 | 2026-03-01 | 2026-03-10 |
| NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease MER511 (IV), Placebo comparator (IV), MER511 (SC) - Graves Disease | Phase 1 | Recruiting | Merida Biosciences | 100 | 2025-12-19 | 2026-10-29 |
| A Study of GensSci098 in Subjects With Graves' Disease GenSci098 - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 24 | 2025-11-21 | 2026-02-17 |
| A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants Teprotumumab, Placebo - Healthy Volunteers | Phase 1 | Completed | Amgen | 20 | 2025-08-26 | 2026-02-27 |
| Study of BHV-1300 in Graves' Disease BHV-1300 - Graves Disease | Phase 1 | Recruiting | Biohaven Therapeutics Ltd. | 15 | 2025-08-21 | 2026-07-31 |
| Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) Kamuvudine-9 - Thyroid Eye Disease | Phase 1 | Terminated | Peter Timoney | 4 | 2024-11-06 | 2026-04-01 |
| A Study of GenSci098 in Subjects With Active Thyroid Eye Disease GenSci098, GenSci098 Placebo - Safety, Tolerability | Phase 1 | Recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 76 | 2024-09-24 | 2026-02-11 |
| A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease Lu AG22515 - Thyroid Eye Disease | Phase 1 | Active not recruiting | H. Lundbeck A/S | 20 | 2024-09-19 | 2026-09-09 |
| A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease AMG 732, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Active not recruiting | Amgen | 94 | 2024-05-30 | 2026-08-10 |
| Study of ZB001 in Chinese Patients With Thyroid Eye Disease ZB001 for injection - Thyroid Eye Disease | Phase 1 | Completed | Zenas BioPharma (USA), LLC | 17 | 2023-05-10 | 2025-04-11 |
| A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants Teprotumumab - Healthy Volunteers | Phase 1 | Completed | Amgen | 44 | 2023-03-24 | 2024-11-05 |
| Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) lonigutamab, Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | ACELYRIN Inc. | 31 | 2023-02-14 | 2025-07-01 |
| A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease Teprotumumab - Thyroid Eye Disease | Phase 1 | Completed | Amgen | 16 | 2022-07-14 | 2024-06-21 |
| A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease LASN01, Placebo - Pulmonary Fibrosis, Thyroid Eye Disease | Phase 1 / Phase 2 | Completed | Lassen Therapeutics 1 PTY LTD | 75 | 2022-06-06 | 2024-12-30 |
Showing 20 of 32. Sign in to see all of them.
Graves Ophthalmopathy (21) · Graves Disease (13) · Autoimmune Diseases (4) · Hyperthyroidism (4) · Thyroid Diseases (4) · Endocrine System Diseases (3) · Eye Diseases (3) · Eye Diseases, Hereditary (2) · Immune System Diseases (2) · Autoimmune Pancreatitis (1) · Cardiovascular Abnormalities (1) · Exophthalmos (1) · Goiter (1) · Inflammation (1)
Exophthalmos (29) · Eye Diseases (29) · Goiter (29) · Immune System Diseases (29) · Autoimmune Diseases (27) · Endocrine System Diseases (27) · Hyperthyroidism (26) · Thyroid Diseases (26) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (22) · Genetic Diseases, Inborn (21) · Eye Diseases, Hereditary (19) · Graves Disease (17) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
Rituximab (4) · teprotumumab (4) · Atorvastatin (1) · Azithromycin (1) · Chlortetracycline (1) · Dexamethasone (1) · Doxycycline (1) · Immunization (1) · Injections (1) · Methimazole (1) · Methylprednisolone (1) · salicylhydroxamic acid (1) · sulfadiazine, tetroxoprim drug combination (1)
Amgen (5) · Changchun GeneScience Pharmaceutical Co., Ltd. (2) · ACELYRIN Inc. (1) · AV7 Limited (1) · Apitope International NV (1) · Banu Aji Dibyasakti (1) · Biohaven Therapeutics Ltd. (1) · Candid Therapeutics (1) · Ethyreal Bio, Inc. (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · H. Lundbeck A/S (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Kriya Therapeutics, Inc. (1) · Lassen Therapeutics 1 PTY LTD (1) · Massachusetts General Hospital (1)
United States (12) · China (9) · Australia (4) · Italy (2) · Poland (2) · Spain (2) · United Kingdom (2) · Bosnia and Herzegovina (1) · Bulgaria (1) · Canada (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Hong Kong (1)
Arezou Khosroshahi, MD (1) · Dan Liang, MD (1) · Daniel El-Fassi, MD (1) · Dave Singh, Professor (1) · Eric B Suhler, MD (1) · Hadas Kalish, MD (1) · Huifang Zhou, PHD (1) · James T Rosenbaum, MD (1) · John H Stone, MD, MPH (1) · Mario Salvi, MD (1) · Peter Timoney (1) · Rona Z Silkiss, MD (1) · Simon HS Pearce (1)
PMID 18299459, PMID 19850691, PMID 22219499, PMID 24652467, PMID 25667206, PMID 26221138, PMID 42660999
2023 (1), 2025 (1)